Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 16:05 ET | Source: PennantPark Floating Rate Capital Ltd.

PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution of $0.1025 per Share

MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) declares its monthly distribution for December 2025 of $0.1025 per share, payable on...
December 02, 2025 07:11 ET | Source: Gilat Satellite Networks Ltd.

Gilat Receives Approximately $10 Million Order for Direct Downlink Earth Observation Solution

PETAH TIKVA, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services,...
November 30, 2025 12:24 ET | Source: Ellomay Capital Ltd

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Three and Nine Months Ended September 30, 2025

TEL AVIV, Israel, Nov. 30, 2025 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable...
November 26, 2025 07:30 ET | Source: Alarum Technologies Ltd.

Alarum Technologies Reports Record Third Quarter Revenue Growth of 81% to $13 Million Driven by Surging Demand from Leading AI Model Developers

TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced...
November 26, 2025 07:00 ET | Source: Can-Fite BioPharma Ltd.

Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

RAMAT GAN, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
November 25, 2025 19:06 ET | Source: Teva Pharmaceutical Industries Ltd

Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva®

Aufgrund der positiven Stellungnahmen des Ausschusses für Humanarzneimittel (CHMP) hat die Europäische Kommission die Zulassungen für die Biosimilars PONLIMSI und DEGEVMA von Teva erteilt und damit...
November 25, 2025 19:06 ET | Source: Teva Pharmaceutical Industries Ltd

Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®

Suite aux avis favorables rendus par le Comité des médicaments à usage humain (CMUH), la Commission européenne a accordé des autorisations de mise en marché visant les biosimilaires PONLIMSI et...
November 25, 2025 17:16 ET | Source: UMH Properties, Inc.

UMH PROPERTIES, INC. ANNOUNCES ADDITION TO FANNIE MAE CREDIT FACILITY

FREEHOLD, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH) announced that on November 25, 2025 it completed the addition of seven communities containing 1,765...
November 25, 2025 08:10 ET | Source: Teva Pharmaceutical Industries Ltd

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA...
November 25, 2025 07:30 ET | Source: BrainsWay

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation...